Last Updated: 2012-03-20

Tekmira Pharmaceuticals Corporation

Company information

Legal Name:   Tekmira Pharmaceuticals Corporation
Operating Name:   Tekmira Pharmaceuticals Corporation
Mailing Address 100-8900 Glenlyon Parkway BURNABY, British Columbia V5J 5J8	Location Address 100-8900 Glenlyon Parkway BURNABY, British Columbia V5J 5J8
Telephone: (604) 419-3200
Fax: (604) 419-3201
Email: info@tekmirapharm.com
Website URL: http://www.tekmirapharm.com

Contact information

Ian Mortimer
	Title:   Vice President
	Area of Responsibility:   Management Executive
	Telephone:   (604) 419-3200
	Fax:   (604) 419-3201
	Email:   imortimer@tekmirapharm.com

Company description

Tekmira is a leader in the development of therapeutic agents based upon Nobel Prize winning breakthroughs in the field of gene silencing, known as RNA interference (RNAi). Tekmira's three lead RNAi product candidates target cholesterol management, cancer and Ebola infection. In addition to its pipeline of products, Tekmira has collaborative or partnership agreements with leading companies in the RNAi field, including Alnylam, Pfizer, Takeda, Bristol-Myers Squibb, and Merck.
Country of Ownership:	Canada
Year Established:	2008
Exporting:	Yes
Primary Industry (NAICS):	325410 - Pharmaceutical and Medicine Manufacturing
Alternate Industries (NAICS):	541710 - Research and Development in the Physical, Engineering and Life Sciences
Primary Business Activity:	Manufacturer / Processor / Producer
Number of Employees:	85

Product / Service / Licensing

Service Name:	Development of therapeutic agents based upon Nobel Prize winning breakthroughs in the field of gene silencing, known as RNA interference (RNAi)

Technology profile

As the fields of genetics, medicine and therapeutics continue to converge, the management of illness at its genetic source by silencing genes via RNA interference (RNAi) holds the very real potential to revolutionize treatment on a scale not seen in decades. Tekmira is one of a handful of biotech companies around the world working to exploit the potential of RNAi to treat disease. And it is from among these unique companies that the next wave of therapeutic breakthroughs will emerge.

Tekmira is uniquely equipped to become a force in this field. Guided by a cohesive vision, the Company possesses leading technology capabilities and a solid intellectual property portfolio in the area of using lipid nanoparticle (LNP) technology to deliver siRNA (small interfering RNA) as well as other nucleic acids in the treatment of disease.

With two RNAi drug candidates in clinical development and another in preclinical development, Tekmira is well positioned to aggressively advance its product strategy. In addition, Tekmira has collaborative or partnership agreements with leading companies in the RNAi field, including Alnylam, Pfizer, Takeda, Bristol-Myers Squibb, and Merck.

Finally, broad manufacturing capabilities and a strong capital position permit the Company to move forward decisively and build a solid base for both near and longer term growth.

Market profile

Industry sector market interests:

• Medical/Biotechnology/Chemical